The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone

BACKGROUND: Denosumab (Xgeva(TM)) is a fully human antibody to RANK-Ligand, an important signal mediator in the pathogenesis of giant cell tumour of bone (GCTB). The use of denosumab in the treatment of GCTB has changed the way in which these tumours are managed over the past years. CASE PRESENTATIO...

Descripción completa

Detalles Bibliográficos
Autores principales: Weschenfelder, Wolfram, Abrahams, John M., Johnson, Luke J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856762/
https://www.ncbi.nlm.nih.gov/pubmed/33530997
http://dx.doi.org/10.1186/s12957-021-02143-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856762/
https://www.ncbi.nlm.nih.gov/pubmed/33530997
http://dx.doi.org/10.1186/s12957-021-02143-3

Ejemplares similares